Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-21. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
=== 21st century === Heather C. Allen, American chemist whose research focuses air-liquid interfaces Rommie Amaro, American chemist focusing on development of computational methods in biophysics for applications to drug discovery. Emily Balskus, American organic and biological chemist, and microbiologist. Recipient of the 2020 Alan T. Waterman Award for her work on understanding the chemistry of metabolic processes. Professor at Harvard University. Natalie Banerji, Swiss chemist and Professor of Chemistry at the University of Bern who studies organic and hybrid materials using ultrafast spectroscopies. Margaret Brimble, New Zealand chemist whose research has included investigations of shellfish toxins and means to treat brain injuries. Jane P. Chang, chemical engineer, materials scientist and professor at UCLA known for her research developing advanced atomic layer deposition (ALD) and etching techniques with applications in microelectronics and energy storage devices. Sherry Chemler, American Organic Chemist. Professor University at Buffalo. ACS Cope Scholar Award recipient (2017). Paulette Clancy, British chemist focusing on computational and machine learning methods, particularly chemistry-informed Bayesian optimization, to model the behavior of semiconductor materials. Sheila Hobbs DeWitt, American chemist. Chair, President, CEO, Cofounder of DeuteRx which has developed PXL065 a Deuterated drug. ACS Kathryn C. Hach Award for Entrepreneurial Success (2025). She is a pioneer of Combinatorial Chemistry.
There are more than 200 groups that we've been able to recognize that call themselves a Cherokee nation, tribe, or band," said Mike Miller, spokesman for the Cherokee Nation. "Only three are federally recognized, but the other groups run the gamut of intent. Some are basically heritage groups – people who have family with Cherokee heritage who are interested in the language and culture, and we certainly encourage that," said Miller. "But the problem is when you have groups that call themselves 'nation', or 'band', or 'tribe', because that implies governance. In 2008, the Cherokee Nation passed the Cherokee Nation Truth in Advertising for Native Art. This law states that only citizens of the three federally recognized Cherokee tribes can sell their artwork, books, or other creative works as being "Cherokee."
Arby's promoted their announcement by breaking two Guinness World Records. The first record, "world's smallest advertisement", measured 38.3 microns by 19.2 microns on a sesame seed and was printed at Georgia Tech. The second record, "largest advertising poster", took up approximately 5 acres of land and was placed in Monowi, Nebraska, America's smallest town. Toasted Subs, sandwiches served on a toasted ciabatta roll, were first introduced in September 2007. The initial line-up included the French Dip & Swiss Toasted Sub, Philly Beef Toasted Sub, Classic Italian Toasted Sub, and Turkey Bacon Club. Three months later, the Toasted Subs product line was extended to include the Meatball Toasted Sub and the Chicken Parmesan Toasted Sub. In October 2013, Arby's introduced a Smokehouse Brisket sandwich. In September 2014, Arby's introduced gyros to its menu for a limited time. Gyros were previously offered in 2006. They have since become a permanent menu fixture on the menu in April 2016. On an almost annual basis, Arby's had offered some sort of a flatbread melt sandwich for a limited time. In 2007 and again in 2008, it was the Philly Cheesesteak and the Fajita Beef. The Beef Fajita returned with the new Chicken Fajita in 2009. After a six-year hiatus, Steak Fajita Flatbreads were offered for a limited time in 2015. The following year, Steak Fajita returned in 2016 with Chicken Fajita along with a choice between a hot and mild sauce. After a nine-year hiatus, a pork-beef mixture meatball sandwich was reintroduced in July 2016.
=== Lactose fermentation === In one study that sought to prove that some fermentation produced by L. lactis can hinder motility in pathogenic bacteria, the motilities of Pseudomonas, Vibrio, and Leptospira strains were severely disrupted by lactose utilization on the part of L. lactis. Using flagellar Salmonella as the experimental group, the research team found that a product of lactose fermentation is the cause of motility impairment in Salmonella. It is suggested that the L. lactis supernatant mainly affects Salmonella motility through disruption of flagellar rotation rather than through irreversible damage to morphology and physiology. Lactose fermentation by L. lactis produces acetate that reduces the intracellular pH of Salmonella, which in turn slows the rotation of their flagella. These results highlight the potential use of L. lactis for preventing infections by multiple bacterial species.
Sources: en.wikipedia.org
=== Kröhnke pyridine synthesis === In the Kröhnke pyridine synthesis, an N-pyridine-substituted methyl ketone is used as the reactant. This compound enters the keto-enol equilibrium and reacts with an enone via a Michael addition. A 1,5-dicarbonyl compound is formed, one carbonyl group of which is replaced by ammonia (or a synthesis equivalent) to form an imine. This intermediate subsequently cyclizes to give a pyridine. The reaction is named after Fritz Kröhnke, who developed it for the preparation of 2,4,6-triarylpyridines and published it in 1961.
Becky's absence is written as her dropping out of high school to elope with Mark and moving to Minneapolis. Producers, however, wanted the character to return but, with Goranson unavailable, they recast the role with Canadian actress Sarah Chalke. Chalke appeared as Becky starting mid-Season 6 and all of Season 7. Goranson returned as Becky for Season 8. When Goranson's school schedule occasionally conflicted with her filming schedule, Chalke filled in. Goranson, not wanting to put the show through more scheduling conflicts, declined to sign on for Season 9 so Chalke returned full time. In the series revival, Goranson once again played Becky. In Season 10, Goranson, as Becky, and Chalke, as a character named Andrea, meet and comment on how much they resemble one another. The Andrea character hires Becky to be her surrogate; this arrangement fails due to Becky's age (she is 43) making it unlikely she can conceive. In Season 1 of The Conners, which deals with life after Roseanne's death from an accidental opiate overdose, Becky, who never expected to get pregnant, announces she is expecting. The child's father, Becky's restaurant coworker Emilio, is an undocumented immigrant from Mexico and unable to help out financially, as he is a small-wage earner. With her family's support, Becky proceeds with the pregnancy. Becky likes but does not love Emilio, though she later warms to him and accepts his being part of her and her child's lives; Dan hires him as a drywall worker at his construction business, and Jackie tutors him in English.
== Side effects == Cyclofenil is associated with a relatively high incidence of hepatotoxicity. Biochemical signs of undesirable liver changes have been observed in 35% or more of individuals and 1% of individuals experience overt hepatitis.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.